{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T18:25:18Z","timestamp":1769279118485,"version":"3.49.0"},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Various treatments exist for nail psoriasis (NP). We determined the relative efficacy of various monotherapies through Bayesian network meta\u2010analyses (NMAs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically reviewed the literature to identify eligible studies which\u2014within the patient, intervention, comparator, outcome (PICO) context\u2014determined the impact of biologic monotherapies on NP in terms of two outcome measures, namely, (1) the 16 to 24\u2010week mean change in the Nail Psoriasis Severity Index (NAPSI) (i.e., outcome 1), and (2) the proportion who attained a Physician Global Assessment of fingernails (PGA\u2010f) of \u201c0\u201d or \u201c1\u201d (i.e., \u201cclear\u201d or \u201calmost clear\u201d) between 16 and 24\u2009weeks (i.e., outcome 2). Our NMAs estimated the surface under the cumulative ranking curve (SUCRA) values and pairwise relative effects. We also determined relative effects of comparators that had never been compared for this condition, including \u201cdeucravacitinib 6mg daily\u201d, \u201crisankizumab 150\u2009mg at weeks 0, 4, 16\u201d, and \u201cgolimumab 2mg\/kg at weeks 0, 4, then every 8\u2009weeks\u201d.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and Conclusion<\/jats:title>\n                    <jats:p>We identified 22 active comparators; \u201ctofacitinib 10 mg twice daily\u201d was ranked most efficacious in terms of 16 to 24\u2010week mean change in NAPSI (SUCRA\u2009=\u200999.71%)\u2014while \u201cixekizumab 160 mg at week 0 followed by 80 mg every 4\u2009weeks\u201d was ranked most efficacious (SUCRA\u2009=\u200995.67%) for proportion attaining PGA\u2010f of 0 or 1 (i.e., outcome 2). Our analyses produced comparative evidence for the relative efficacy of monotherapies with various agents, including biologics and non\u2010biologics. Our findings would guide clinical decision\u2010making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jocd.70657","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:56:43Z","timestamp":1767851803000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Relative Effects of Monotherapies for Psoriatic Nails: A Network Meta\u2010Analysis Study"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Mediprobe Research Inc.  London Ontario Canada"},{"name":"Division of Dermatology, Temerty Faculty of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary A.","family":"Bamimore","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc.  London Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Wang","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc.  London Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0691-640X","authenticated-orcid":false,"given":"Mesbah","family":"Talukder","sequence":"additional","affiliation":[{"name":"School of Pharmacy BRAC University  Dhaka Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.7861\/CLINMED.2021\u20100257"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555\u20103384"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.2983"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806\u20104841.20142633"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12529\u2010016\u20109617\u20100"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/BS10090142"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0031\u20109384(00)00290\u20100"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.15570\/actaapa.2018.38"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555\u20103640"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2263108"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad136"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.024"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14\u20102385"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.5195\/jmla.2017.88"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472\u20106947\u20107\u201016"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643\u2010024\u201002619\u20109"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643\u2010016\u20100384\u20104"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102019\u2010215386"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0793"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(17)31429\u20100"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12060"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19509"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2011.646939"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.736960"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403\u2010024\u201003036\u20107"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17931"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010020\u201000383\u2010x"},{"key":"e_1_2_12_31_1","unstructured":"ClinicalTrials.gov NCT03611751 an Investigational Study to Evaluate Experimental Medication BMS\u2010986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate\u2010to\u2010Severe Plaque Psoriasis (POETYK\u2010PSO\u20102)(2022) accessed September 10 2025 https:\/\/clinicaltrials.gov\/search?cond=NCT03611751."},{"key":"e_1_2_12_32_1","unstructured":"ClinicalTrials.gov Effectiveness and Safety of BMS\u2010986165 Compared to Placebo and Active Comparator in Participants With Psoriasis (POETYK\u2010PSO\u20101) https:\/\/clinicaltrials.gov\/study\/NCT03624127."},{"key":"e_1_2_12_33_1","unstructured":"ClinicalTrials.gov NCT01276639 a One\u2010Year Study to Evaluate the Effects and Safety of CP\u2010690550 in Patients With Moderate to Severe Chronic Plaque Psoriasis https:\/\/clinicaltrials.gov\/study\/NCT01276639."},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11180"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468\u20103083.2010.03927.x"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40851"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijdvl.IJDVL_73_16"},{"key":"e_1_2_12_38_1","volume-title":"Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis","author":"ClinicalTrials.gov"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1428"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1167"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.3758\/s13423\u2010016\u20101170\u2010y"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.70657","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jocd.70657","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.70657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:14:29Z","timestamp":1769228069000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.70657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/jocd.70657"],"URL":"https:\/\/doi.org\/10.1111\/jocd.70657","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70657"}}